A new hope for idiopathic pulmonary fibrosis
- PMID: 24836311
- DOI: 10.1056/NEJMe1403448
A new hope for idiopathic pulmonary fibrosis
Comment on
-
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Clinical Trial.
-
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836312 Clinical Trial.
Similar articles
-
Treatments for idiopathic pulmonary fibrosis.N Engl J Med. 2014 Aug 21;371(8):781. doi: 10.1056/NEJMc1407776. N Engl J Med. 2014. PMID: 25140968 No abstract available.
-
Treatments for idiopathic pulmonary fibrosis.N Engl J Med. 2014 Aug 21;371(8):783-4. doi: 10.1056/NEJMc1407776. N Engl J Med. 2014. PMID: 25147884 No abstract available.
-
Treatments for idiopathic pulmonary fibrosis.N Engl J Med. 2014 Aug 21;371(8):782. doi: 10.1056/NEJMc1407776. N Engl J Med. 2014. PMID: 25140971 No abstract available.
-
The safety of new drug treatments for idiopathic pulmonary fibrosis.Expert Opin Drug Saf. 2016 Nov;15(11):1483-1489. doi: 10.1080/14740338.2016.1218470. Epub 2016 Aug 17. Expert Opin Drug Saf. 2016. PMID: 27532218 Review.
-
Clinical trial research in focus: why do so many clinical trials fail in IPF?Lancet Respir Med. 2017 May;5(5):372-374. doi: 10.1016/S2213-2600(17)30122-4. Epub 2017 Apr 12. Lancet Respir Med. 2017. PMID: 28412184 Review. No abstract available.
Cited by
-
Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis.Thorax. 2015 Jan;70(1):48-56. doi: 10.1136/thoraxjnl-2013-204596. Epub 2014 Sep 12. Thorax. 2015. PMID: 25217476 Free PMC article.
-
Idiopathic pulmonary fibrosis: pathogenesis and management.Respir Res. 2018 Feb 22;19(1):32. doi: 10.1186/s12931-018-0730-2. Respir Res. 2018. PMID: 29471816 Free PMC article. Review.
-
Discovery of Indolinone-Based Multikinase Inhibitors as Potential Therapeutics for Idiopathic Pulmonary Fibrosis.ACS Med Chem Lett. 2017 Sep 30;8(11):1142-1147. doi: 10.1021/acsmedchemlett.7b00164. eCollection 2017 Nov 9. ACS Med Chem Lett. 2017. PMID: 29152045 Free PMC article.
-
Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.Drugs. 2015 Jul;75(10):1131-40. doi: 10.1007/s40265-015-0418-6. Drugs. 2015. PMID: 26063212 Review.
-
Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis.Transl Res. 2015 Dec;166(6):554-67. doi: 10.1016/j.trsl.2015.09.004. Epub 2015 Sep 18. Transl Res. 2015. PMID: 26432923 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources